| abstract |
The present invention relates to a simple process for the modification of, e.g., anti-TAA antibodies, which alters their immunogenicity so that their ability to induce an anti-isotypic response is selectively diminished, while they remain able to elecit an anti-idiotypic response. The latter is of potential immunotherapeutic value, i.e., by activation of the idiotype-anti-idiotype network. This modification takes the form of a controlled and partial reduction of the antibody; effector regions are retained. The invention should permit repeat injections (for diagnosis and therapy) and reduce HAMA interference in serodiagnostic assays. |